The Role of ITGAM in Systemic Lupus Erythematosus
NCT01230112 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40
Last updated 2013-07-30
Summary
Study to examine the role of ITGAM molecule in normal control subjects with known genetic variation in the ITGAM gene.
Conditions
Sponsors & Collaborators
-
National Institute of Allergy and Infectious Diseases (NIAID)
collaborator NIH -
Northwell Health
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 90 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2009-12-31
- Primary Completion
- 2012-04-30
- Completion
- 2012-04-30
Countries
- United States
Study Locations
More Related Trials
-
Determining the Responses and Impact of Rituximab-instigated Cell Depletion on T Cells in People With SLE
NCT01702038 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus
NCT00137969 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Role of Antibodies in Cognitive Dysfunction in Patients With Systemic Lupus Erythematosus
NCT00042523 ·Status: COMPLETED
-
Autoreactivity Threshold Analysis in Lupus and Immune Thrombocytopenia (Checkpoints ITP and SLE)
NCT03975361 ·Status: UNKNOWN ·Phase: NA
-
Utilizing Qualitative and Quantitative Methods to Understand a New Model of Type 1 and 2 Systemic Lupus Erythematosus (SLE)
NCT05426902 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Safety of Telitacicept in Early SLE
NCT05899907 ·Status: UNKNOWN ·Phase: PHASE4
-
Role of Altered CD40-Ligand Gene Transcription in Systemic Lupus Erythematosus
NCT00008749 ·Status: UNKNOWN
-
T Regulatory Cells IN LUPUS NEPHRITIS
NCT06428539 ·Status: NOT_YET_RECRUITING
-
Safety and Efficacy of Telitacicept in the Treatment of Systemic Lupus Erythematosus (SLE)
NCT06458972 ·Status: RECRUITING
-
A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old
NCT06064929 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Effect of Telitacicept on Transitional Regulatory B Cells in Patients With Systemic Lupus Erythematosus
NCT06137053 ·Status: RECRUITING
-
Association of Serum Interleukin-33 Levels With Clinical Manifestations in Systemic Lupus Erythematosus
NCT07149402 ·Status: NOT_YET_RECRUITING
-
Disease Progression and Activity in Patients With Systemic Lupus Erythematosus
NCT00339261 ·Status: COMPLETED
-
Phase 1 Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)
NCT00657007 ·Status: COMPLETED ·Phase: PHASE1
-
Highly Sensitive Serum Cardiac Troponin T and Cardiovascular Events in Patients With Systemic Lupus Erythematosus
NCT04580108 ·Status: COMPLETED
-
Autologous Stem Cell Transplantation: International Lupus Trial
NCT05063513 ·Status: WITHDRAWN ·Phase: PHASE2/PHASE3
-
Clonal Hematopoiesis of Indeterminate Potential and Accelerated Atherosclerosis in Systemic Lupus Erythematosus
NCT05146414 ·Status: COMPLETED
-
A Study of rhuMAb IFNalpha in Adults With Systemic Lupus Erythematosus
NCT00541749 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Neonatal IgG Fc Receptor Expression in Natural Killer T Cells Expressing an Invariant T Receptor : Implication in the Pathophysiology of Systemic Lupus
NCT05859191 ·Status: RECRUITING
-
Comparison of the Efficacy of Two Rituximab Treatment Regimens in Patients With Lupus Nephropathy
NCT01765842 ·Status: TERMINATED ·Phase: PHASE3
-
Serologically Active, Clinically Stable Systemic Lupus Erythematosus
NCT00000421 ·Status: COMPLETED ·Phase: PHASE2
-
Autophagy in Systemic Lupus Erythematosus
NCT03583853 ·Status: UNKNOWN
-
Rituximab and Belimumab for Lupus Nephritis
NCT02260934 ·Status: COMPLETED ·Phase: PHASE2
-
Rituximab Objective Outcome Measures Trial in SLE
NCT03054259 ·Status: UNKNOWN ·Phase: PHASE2
-
Addressing Disparities in Lupus Care Through an Integrated Care Management Program
NCT03915652 ·Status: COMPLETED ·Phase: NA